New arthritis drug trial for kids: could filgotinib help?
NCT ID NCT06222034
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing the drug filgotinib in children aged 8 to 17 with juvenile idiopathic arthritis (JIA), a condition causing joint pain and swelling. The goal is to see how the drug moves through the body and if it is safe. Ten children with moderate to severe JIA that is not well controlled by current treatments will take filgotinib once daily for several weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
filgotinib (Jyseleca)
What this could lead to
If successful, this could provide a new treatment option for children with juvenile idiopathic arthritis that is not well controlled by current therapies.
What could go wrong
This is a very early (Phase 1) study with only 10 participants, so results may not apply to all children. The drug may cause side effects or not work as well as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asklepios Klinik Sankt Augustin GmbH
NOT_YET_RECRUITINGSankt Augustin, 53757, Germany
-
Bicêtre University Hospital
RECRUITINGLe Kremlin-Bicêtre, 94270, France
-
CHU Amiens - Hopital Nord
RECRUITINGAmiens, 80054, France
-
Children's university hospital Charité, Campus Virchow, SPZ
RECRUITINGBerlin, 13353, Germany
-
Great Ormond Street Hospital
NOT_YET_RECRUITINGLondon, WC1N 3JH, United Kingdom
-
Hamburger Zentrum fur Kinder und Jugendrheumatologie
RECRUITINGHamburg, 22081, Germany
-
Hospital Sant Joan de Deu
RECRUITINGBarcelona, 08950, Spain
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitari i Politecnic La Fe
RECRUITINGValencia, 46026, Spain
-
Malopolskie Badania Kliniczne
RECRUITINGKrakow, 30-002, Poland